Novabridge Biosciences
SEC CIK 1778016 · NBP · last insider filing 2026-06-30
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Fu Wei | Director | filed 2026 - 2026 |
| Cao Sean Wuxiong | Director · See Remarks | filed 2026 - 2026 |
| Yang Conor Chia-Hung | Director | filed 2026 - 2026 |
| Au Chun Kwok Alan | Director | filed 2026 - 2026 |
| Cunningham Emmett | Director | filed 2026 - 2026 |
| Lenz Robert A. | Director | filed 2026 - 2026 |
| Fu Xi-Yong | Director · See Remarks | filed 2026 - 2026 |
| Woo Ian Ying | Director | filed 2026 - 2026 |
| Liu Xin | Director | filed 2026 - 2026 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Dennis Phillip Andrew | Chief Medical Officer | filed 2026 - 2026 |
| Xu Cong Claire | See remarks | filed 2026 - 2026 |
| Hagler Mark Arnold | See Remarks | filed 2026 - 2026 |
| Chu Denny Hsueh Wen | See Remarks | filed 2026 - 2026 |
| Lei Ming Kyler | Chief Financial Officer | filed 2026 - 2026 |
| Zhang Adeline Yi | Global Controller | filed 2026 - 2026 |
| Wu Joanna Xuqiong | See Remarks | filed 2026 - 2026 |
| Lin Liwei Lorraine | General Counsel | filed 2026 - 2026 |
| Zhang Xiaofan Neo | Chief Investment Officer | filed 2026 - 2026 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.